A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Xenon Pharmaceuticals Inc.
400 participants
Aug 8, 2025
INTERVENTIONAL
Conditions
Summary
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
Eligibility
Inclusion Criteria4
- Adults ≥18 and ≤74 years of age who experienced their first major depressive episode (MDE) prior to 50 years of age.
- Body Mass Index (BMI) ≥18 kg/m2 and ≤40 kg/m2.
- Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder and is currently in a MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI).
- Current MDE must has a duration of ≥4 weeks and ≤12 months.
Exclusion Criteria12
- Participant has any type of major depressive disorder (MDD) diagnosis, including MDD with psychotic features, MDD with catatonia, MDD with seasonal pattern, or postpartum depression.
- Participant has any nonbipolar psychiatric diagnosis.
- Participant has a substance use disorder (excluding tobacco) within the 6 months prior to screening visit.
- Participant has a symptomatic eating disorder within the 12 months prior to screening visit.
- Participant has a Young Mania Rating Scale (YMRS) score \>12 points at screening visit or randomization.
- Participant has been hospitalized for mania within the 30 days prior to screening visit.
- Participant is considered treatment-resistant in the current bipolar depressive episode, defined as having treatment resistance (no remission) to ≥2 different medications approved by the regional regulatory authority at an adequate dose (per regulatory approved label) and for an adequate duration (at least 6 weeks).
- Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 12 months.
- Participant has self-injurious behavior without intent to die in the 12 months prior to screening.
- Participant has used antidepressants, mood stabilizers, anticonvulsants, antipsychotics, or other prohibited medications within the 1 week or within a period less than 5 times the drug's half-life, whichever is longer prior to randomization.
- Participants with medical conditions that may interfere with the purpose or conduct of the study.
- Participant is pregnant, breastfeeding, or planning to become pregnant.
Interventions
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07172516